Dopamine: A Marker of Psychosis and Final Common Driver of Schizophrenia Psychosis

Henn, F. A. (December 2011) Dopamine: A Marker of Psychosis and Final Common Driver of Schizophrenia Psychosis. American Journal of Psychiatry, 168 (12). pp. 1239-1240. ISSN 0002-953X

[thumbnail of Paper]
PDF (Paper)
Henn American Journal of Psychiatry 2011.pdf - Published Version

Download (71kB) | Preview
DOI: 10.1176/appi.ajp.2011.11091346


Our attempt to understand schizophrenia in neurochemical terms began with the landmark studies of Carlsson and Lindqvist (1) in the 1960s. The results of these studies, based on the action of chlorpromazine, were strengthened by the binding studies carried out in both Seeman's (2) and Synder's (3) laboratories, which showed that antipsychotic potency was correlated with dopamine D2 receptor binding. The one major exception to this correlation is clozapine, which appears to be the most effective available drug for treating schizophrenia symptoms. The most recent version of the resulting dopamine hypothesis suggests that genetic, environmental, and developmental variables play major etiological roles in schizophrenia, but that striatal dopamine presynaptic overactivity remains the final trigger resulting in psychosis......

Item Type: Paper
Additional Information: The official published article is available online at
Uncontrolled Keywords: high-risk drugs
Subjects: diseases & disorders
diseases & disorders > mental disorders
diseases & disorders > mental disorders > schizophrenia
CSHL Authors:
Communities: CSHL labs > Henn lab
Depositing User: Matt Covey
Date: December 2011
Date Deposited: 07 Feb 2013 16:09
Last Modified: 07 Feb 2013 16:09
Related URLs:

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving